MedTrace Logo

Multicenter Clinical Study on the Optimal Treatment Protocol and Outcome of Cough Variant Asthma With Chinese and Western Medicine

NCT05459805 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 164

Last updated 2023-01-31

No results posted yet for this study

Summary

To explore the disease outcome prognosis of cough variant asthma by observing the outcomes of cough variant asthma and the effects of Chinese and Western medicine interventions, and to provide a scientific basis for optimizing the treatment protocol of combined traditional and Western medicine for cough variant asthma. This is a multi-center, non-randomized, prospective cohort study. This study started in March 2022 and is going on now. On an informed consent basis, a cohort of 164 patients with diagnosis of CVA are engaged. All patients will receive 8-week treatment (ICS/LABA plus Chinese herbal medicine for trial group while ICS/LABA only for control group) and be observed in next 24 weeks. Patients will be followed up every 2 weeks during treatment period and every 4 weeks in observation.The feasibility and correctness of the study will be supervised by two supervisors. To ensure that participants adhere to their follow-up plans, we remind them of their fixed visiting by phone or message. Additionally, incentives are used to appreciate participants for their cooperation.

Conditions

  • Cough Variant Asthma

Interventions

DRUG

traditional chinese medicine Xuanfei-Zhike formula

200ml, bid, for 8 weeks

DRUG

inhaled corticosteroids (ICS) and long-acting β2-agonist (LABA)

one suction, q12h, for 8 weeks

Sponsors & Collaborators

  • Xin Hua Hospital of Zhejiang Province

    collaborator OTHER

  • Hangzhou Hospital of Traditional Chinese Medicine

    collaborator OTHER

  • Affiliated Wenling Hospital of Wenzhou Medical University

    collaborator OTHER

  • The First Affiliated Hospital of Zhejiang Chinese Medical University

    lead OTHER

Principal Investigators

  • Junchao Yang · The First Affiliated Hospital of Zhejiang Chinese Medical University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05459805 on ClinicalTrials.gov